Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
<p>ORR, CBR<sub>24</sub>, and median PFS for (<b>A</b>) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (<b>B</b>) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and is not representative of the data. N, no; NC, not calculated; Y, yes. Data in % represent 95% CI.</p>
Authors
- Bairu Zhang (ORCID: https://orcid.org/0000-0002-2753-9407)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
- Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
- Iván Victoria (ORCID: https://orcid.org/0000-0002-8733-6089)
- Peter Kabos (ORCID: https://orcid.org/0000-0003-1500-471X)
- Chris Twelves (ORCID: https://orcid.org/0000-0002-1849-7153)
- Andy Sykes (ORCID: https://orcid.org/0000-0003-2257-4841)
- Alastair Mathewson
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Anne Caroline Armstrong (ORCID: https://orcid.org/0000-0002-0774-7006)
- Carmela Ciardullo (ORCID: https://orcid.org/0000-0002-0809-2136)
- Teresa Klinowska (ORCID: https://orcid.org/0000-0003-1997-7340)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Christos Vaklavas (ORCID: https://orcid.org/0000-0002-9919-2748)
- Christopher J. Morrow (ORCID: https://orcid.org/0000-0003-1524-9426)
- Manuel Ruíz-Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
- Irene Moreno (ORCID: https://orcid.org/0000-0001-5027-6388)
- Justin P.O. Lindemann (ORCID: https://orcid.org/0000-0003-1531-9754)
- Jason Incorvati
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Richard D. Baird (ORCID: https://orcid.org/0000-0001-7071-6483)
- Jincheng Yang (ORCID: https://orcid.org/0000-0002-4813-1056)
Publication Details
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/1078-0432.30363357
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00